Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients

Haematologica

Volumn 99, Issue 10, 2014, Pages e182-e184

  Qiao, Chun ^a   Sun, Chao ^a   Ouyang, Yuan ^a   Wang, Ju Juan ^a   Qian, Si Xuan ^a   Li, Jian Yong ^a   Zhang, Su Jiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

calreticulin; Janus kinase 2 mutation; MPL

Indexed keywords

CALRETICULIN; HEMOGLOBIN; JANUS KINASE 2; JAK2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; SEQUENCE ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTHEMIA; GENETICS; MORTALITY; MUTATION; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

CALRETICULIN; HUMANS; JANUS KINASE 2; MUTATION; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84907520020     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.109199     Document Type: Letter

References (11)

1. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-97.
2. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008; 112(6):2190-8.
3. Viny AD, Levine RL. Genetics of myeloproliferative neoplasms. Cancer J. 2014;20(1):61-5.
4. Van Etten RA, Koschmieder S, Delhommeau F, Perrotti D, Holyoake T, Pardanani A, et al. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica. 2011;96(4):590-601.
5. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-405.
6. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-90.
7. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544-51.
8. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552-5.
9. Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, et al. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014;123(15):2416-9.
10. Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220-8.
11. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-33.